During the last session, Aclaris Therapeutics Inc (NASDAQ:ACRS)’s traded shares were 0.83 million, with the beta value of the company hitting 0.42. At the end of the trading day, the stock’s price was $1.45, reflecting an intraday gain of 2.11% or $0.03. The 52-week high for the ACRS share is $5.17, that puts it down -256.55 from that peak though still a striking 27.59% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $157.01M, and the average trade volume was 806.76K shares over the past three months.
Aclaris Therapeutics Inc (ACRS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. ACRS has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Aclaris Therapeutics Inc (ACRS) registered a 2.11% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.11% in intraday trading to $1.45, hitting a weekly high. The stock’s 5-day price performance is -5.23%, and it has moved by 7.41% in 30 days. Based on these gigs, the overall price performance for the year is 28.32%.
The consensus price target of analysts on Wall Street is $7.5, which implies an increase of 80.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $25 respectively. As a result, ACRS is trading at a discount of -1624.14% off the target high and -106.9% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.24%. While earnings are projected to return 67.20% in 2025, the next five years will return 25.55% per annum.
ACRS Dividends
Aclaris Therapeutics Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Aclaris Therapeutics Inc insiders own 2.69% of total outstanding shares while institutional holders control 88.26%, with the float percentage being 90.70%. BML CAPITAL MANAGEMENT, LLC is the largest shareholder of the company, while 137.0 institutions own stock in it. As of 2024-06-30, the company held over 12.99 million shares (or 18.2184% of all shares), a total value of $14.29 million in shares.
The next largest institutional holding, with 4.69 million shares, is of VANGUARD GROUP INC’s that is approximately 6.5752% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.16 million.
